Uzedy Shortage: What Providers and Prescribers Need to Know in 2026

As prescribers of Uzedy (risperidone extended-release injectable suspension for subcutaneous use) are discovering, patient access to this medication can be inconsistent — not due to a manufacturing shortage, but due to the structural realities of specialty drug distribution. This guide is written specifically for psychiatrists, psychiatric NPs/PAs, primary care providers, and clinic administrators who are working to ensure patients can access and remain on Uzedy therapy.

Is Uzedy in an Official FDA Shortage?

No. As of 2026, Uzedy does not appear on the FDA Drug Shortages Database (accessdata.fda.gov/scripts/drugshortages). Teva Pharmaceuticals has not issued any shortage notifications for Uzedy. The access challenges patients face are structural — related to specialty distribution and coverage — rather than supply disruption.

The Clinical Profile of Uzedy: A Quick Review

For providers who may be newer to Uzedy, here is a brief clinical summary:

Indications: Schizophrenia in adults (FDA-approved April 2023); maintenance treatment of bipolar I disorder in adults as monotherapy or adjunct to lithium/valproate (FDA-approved October 2025).

Route: Subcutaneous injection in the abdomen or upper arm. No IM injection required.

Dosing schedule: Once monthly (q1M) or once every 2 months (q2M) for schizophrenia; once monthly for bipolar I disorder maintenance.

Strengths: 50 mg, 75 mg, 100 mg, 125 mg (q1M); 100 mg, 150 mg, 200 mg, 250 mg (q2M).

Oral overlap: Not required. Start Uzedy the day after the last oral dose. No loading dose needed.

Onset: Therapeutic blood concentrations reached within 6–24 hours of first injection, thanks to SteadyTeq™ polymer technology.

Controlled substance status: Uzedy is NOT a controlled substance. No DEA schedule.

Understanding the Access Landscape

Patient access to Uzedy is shaped by several structural factors:

1. Specialty-only distribution. Uzedy is dispensed exclusively through specialty pharmacies. It is not available at standard retail pharmacies. Providers must either maintain a direct specialty pharmacy relationship or use one of Teva's network partners.

2. Medical benefit billing. Uzedy is typically billed under the medical benefit (e.g., Medicare Part B) rather than the pharmacy benefit. This requires provider-side billing coordination and almost always triggers a prior authorization (PA) process. PA approval can take 2–4 weeks — a significant delay for patients who need timely treatment.

3. Geographic disparity. Urban areas with large specialty pharmacy networks generally have better Uzedy access than rural or underserved areas where specialty pharmacy footprint is limited.

Strategies to Improve Patient Access

Engage Teva Total Support™ early. Teva's hub program (1-800-887-8100) offers benefits verification, prior authorization support, and specialty pharmacy linkage. Engage this program at the time of prescribing — before the patient's first injection date — to minimize delays.

Establish an in-clinic dispensing arrangement. If your practice or clinic administers LAI antipsychotics, consider setting up a direct account with a specialty pharmacy to receive Uzedy for in-house administration. Community mental health centers and FQHCs can often access Uzedy through 340B drug pricing programs, which can significantly reduce costs for eligible patients.

Use the peer-to-peer PA process. If a patient's PA is denied, request a peer-to-peer review with the insurance medical director. For schizophrenia and bipolar I disorder maintenance, Uzedy's clinical profile — particularly its unique q2M dosing and rapid onset without oral overlap — can support medical necessity arguments.

Direct patients to medfinder. medfinder for providers helps your patients locate pharmacies that can fill Uzedy near them — by calling pharmacies on their behalf and texting results. This can save significant staff time versus manually calling pharmacies for patients.

When to Consider Clinical Alternatives

If Uzedy access cannot be secured within a clinically appropriate timeframe, consider the following alternatives based on patient-specific factors:

Oral risperidone bridge: Initiate or continue oral risperidone (generic widely available, low cost) while Uzedy sourcing is resolved. Dose conversion is straightforward given identical active ingredients.

Perseris (risperidone SC monthly): Same mechanism, subcutaneous route. Available in 90 mg and 120 mg. May be more accessible at some specialty pharmacies.

Invega Sustenna (paliperidone palmitate, q1M IM): Paliperidone is the primary metabolite of risperidone. Widely stocked, no oral overlap needed.

Abilify Maintena (aripiprazole, q1M IM): Consider for patients where metabolic side effects are a primary concern. Requires 21-day oral overlap.

Key Takeaway for Providers

Uzedy access challenges are solvable with proactive engagement — early hub enrollment, in-clinic dispensing arrangements, and patient support tools. For a detailed step-by-step guide on helping patients access Uzedy, see: How to Help Your Patients Find Uzedy in Stock: A Provider's Guide.